Valued at $15.74 billion in 2020, the medical marijuana market is expected to reach $41 billion by 2026 with a CAGR of 17.79 percent. There are many reasons why the demand for medical marijuana is on the rise. In the United States, the most direct cause of an increase in marijuana consumption is the progressive legalization of medical marijuana across multiple states since the last election. With legalization comes more recognition and acceptance, particularly in the medical field where doctors can now prescribe medical marijuana for a range of issues such as muscle spasms, nausea, poor appetite, nerve pain, and anxiety.
With legalization also comes increased investment potential. Since medical marijuana is a relatively young industry, we are looking at a hyper-growth market where there are very few entrenched players and niche owners. New players are entering the market constantly, keeping it innovative and competitive. Venture capitalists and private funding firms have their eyes trained on the market, with Snoop Dogg’s cannabis-focused Casa Verde pouring millions into cannabis start-ups.
Drugs In Demand
When thinking about cannabis users, people often picture the younger and less conservative demographic getting high to cope with existential dread. So, it might be interesting for investors to remember that baby boomers are now coming to an age where they need pain relief. Let us not forget that many of these boomers grew up through the hippy movement of the 1960s and are more than happy to turn to legal herbs to ease their sore hips and joints. Baby boomers, who were well set up by the post-WWII economic expansion, are known for their deep pockets and purchasing strength. They represent 70 percent of the disposable income in America and are expected to receive $15 trillion worth of inheritance in the near future. With this powerhouse generation getting older, the healthcare field is poised to rake in profits as boomers spend on supplements, pharmaceutical drugs, cosmetic surgery, and—of course—medical marijuana.
As states and regions look to harness the monetary potential of the legal marijuana market, it is expected that licensing will bring a new and welcomed source of tax income, at the same time helping to reform industry standards and create a more robust business environment. From real estate trading of agricultural plots and custom laboratory equipment to research and development, patents, and proprietary blends, there are a myriad of ways that industry players can edge forward in the market. The good news for investors who are leery about legal issues in the US is that even if medical marijuana is illegal in certain states, it is completely legal to trade top medical marijuana stocks of companies in the medical marijuana sector, regardless of where you live. Besides, as stigma around cannabis use dissipates and increasing research proves the benefits of medical marijuana, the market is only going to expand and move forward.
Your Slice of Medical Marijuana
There is no denying that medical marijuana is generating a lot of trading interest. With a few million people suddenly being granted access to medical marijuana for the first time, demand is far outstripping supply. And because it can be legally complicated to transport cannabis (which remains a Class 1 drug in the US) across state and national borders, many businesses have a captive audience. Whenever fresh research is published linking marijuana to a medical treatment, medical marijuana penny stocks heat up. The same applies to news about the legalization of cannabis-facilitating bills such as the 2018 Farm Bill, which resulted in a surge in marijuana stocks. With more and more companies entering the cannabis market and trying to carve out a niche of their own, investors have additional opportunities to profit.
Unfortunately, it can be hard to choose the right stocks to invest in. There are a variety of cultivators, manufacturers, biotech and pharmaceutical companies, distributors, and service providers for investors to choose from. An example of a massive pharmaceutical player is GW Pharmaceuticals (NASDAQ: GWPH), producer of the FDA-approved cannabinoid-based drug Epidiolex. On the other hand, there are many smaller companies that bank on the ancillary with significant potential for growth, including GrowGeneration Corp (NASDAQ: GRWG) who produce specialty hydroponic equipment, and High Tide Inc. (NASDAQ: HITI) who focus on distribution, cannabis-use accessories, and lifestyle products.
While possessing great potential, medical marijuana stocks can be stressful for the nervous investor. Because of the legal ambiguity of marijuana, regulations are almost always in a state of flux. Companies must be prepared to react swiftly to changing laws and remain innovative to retain their share of the market. As with most rapidly expanding industries, many aspiring cannabis-related startups will fail. Some companies may issue more shares to build capital for expansion, causing a drop in the value of the shares that you hold. Therefore, anyone looking to invest in medical marijuana stocks first must undertake some very thorough research. The future for the medical marijuana market seems to be lush and full of promise. By seeking expert advice and doing comprehensive research, investors can benefit from this green revolution.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
Solidarity Day 2022: Ganzourgou Producers Offer 2.6 Tons of Food to Vulnerable People
Regarding the selection criteria of vulnerable people, Ambroise Ouédraogo said that his association collaborates with the provincial directorate of Social...
Ford Chooses Almussafes over Germany for the Production of Electric Models
Thus, the Valencian factory will be the fifth Spanish factory to produce all-electric models. Stellantis manufactures electric models at its...
Surveillance Systems in High Demand as Public Safety Concerns Grow
Public safety concern is a national issue, and government officials are committed to enhancing safety. Surveillance systems of every type...
Delta Med (White Bridge Investments II) Buys AdriaMed’s Infusion Pumps
Delta Med is also active in the production and distribution in Italy and abroad of medical devices and disposable accessories...
Evenfi Raises +300,000 in 24 Hours in its Equity Crowdfunding Round
EvenFi was founded in Bergamo, Italy in 2018 as Criptalia by Diego Dal Cero and Mattia Rossi, and, launched in...
Biotech1 week ago
Satellos Bioscience’s Stem Cell Signaling Research Could Turn the Tables on Muscular Dystrophies
Crypto2 weeks ago
Solana Price Forecast: SOL Forms a Dead Cat Bounce
Crowdfunding2 weeks ago
Exporo Raises Funds, but the Company Value Decreases Instead of Increasing
Featured2 weeks ago
Credimi Structures New €26.6M Securitization to Finance Southern SMEs